Cystic Fibrosis

CFTR Modulator Therapy With Tezacaftor-Ivacaftor in Cystic Fibrosis

CFTR Modulator Therapy With Tezacaftor-Ivacaftor in Cystic Fibrosis

By

Effective cystic fibrosis transmembrane conductance regulator modulator therapy may be of benefit in subsets of patients with cystic fibrosis.

Use of Antibiotic Prophylaxis in Young Children With Cystic Fibrosis

Use of Antibiotic Prophylaxis in Young Children With Cystic Fibrosis

By

In children with cystic fibrosis, risk for first detection of S aureus and P aeruginosa was greater in those who had received antibiotic prophylaxis.

Cystic Fibrosis: More Access to Advanced Care Planning, Palliative Care Needed

Cystic Fibrosis: More Access to Advanced Care Planning, Palliative Care Needed

By

Palliative care access may be limited for patients with cystic fibrosis.

ADHD in Cystic Fibrosis: Prevalence, Screening, and Treatment

ADHD in Cystic Fibrosis: Prevalence, Screening, and Treatment

By

The Adult ADHD Self-Report Scale-v1.1 Symptom Checklist may be able to detect previously undiagnosed ADHD in patients with cystic fibrosis.

Delayed Gastric Motility Post-Lung Transplantation in Patients With No Prior GI Surgery

Delayed Gastric Motility Post-Lung Transplantation in Patients With No Prior GI Surgery

By

Underlying cystic fibrosis may be a risk factor for the prediction of delayed gastric emptying in patients who undergo lung transplantation.

Respiratory Microbiome Changes May Affect Airway Inflammation in Cystic Fibrosis

Respiratory Microbiome Changes May Affect Airway Inflammation in Cystic Fibrosis

By

Lower microbial diversity in the respiratory tract in patients with cystic fibrosis was linked with prophylactic antibiotics and less airway inflammation.

Predicting Severity in Cystic Fibrosis With Sweat Chloride

Predicting Severity in Cystic Fibrosis With Sweat Chloride

By

Sweat chloride can predict severity in patients with CF, especially for long-term lung damage.

Lumacaftor/Ivacaftor Safe, Effective for Pediatric Cystic Fibrosis

Lumacaftor/Ivacaftor Safe, Effective for Pediatric Cystic Fibrosis

By

Combination lumacaftor/ivacaftor therapy was found to be safe and effective in patients with cystic fibrosis aged 6 to 11 years.

FDA Expands Approved Use of Ivacaftor for Cystic Fibrosis

FDA Expands Approved Use of Ivacaftor for Cystic Fibrosis

By

The FDA has expanded the approved indication of ivacaftor for cystic fibrosis, increasing the number of rare gene mutations the drug may be used to treat.

Antibiotic Treatment Improves Acute FEV1 Decline in Cystic Fibrosis

Antibiotic Treatment Improves Acute FEV1 Decline in Cystic Fibrosis

Inpatient antibiotic therapy is associated with greater likelihood of recovery following acute lung function decline in pediatric patients with cystic fibrosis.

Sign Up for Free e-newsletters